Related Experiment Video

Updated: Aug 5, 2026

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program
04:24

A Novel Digital Platform for a Monitored Home-based Cardiac Rehabilitation Program

Published on: April 19, 2019

Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?

G B Mancini1, D J Stewart

  • 1Department of Medicine, University of British Columbia and Vancouver General Hospital, Vancouver, Canada. mancini@interchange.ubc.ca

The Canadian Journal of Cardiology
|May 31, 2001
PubMed

Insights

The Heart Outcomes Prevention Evaluation (HOPE) study demonstrated that ramipril, an ACE inhibitor, significantly reduces cardiovascular events and diabetes complications in high-risk patients. Vitamin E therapy showed no statistical benefits in this trial.

Area of Science:

  • Cardiology
  • Pharmacology
  • Preventive Medicine

Background:

  • High-risk patients face significant cardiovascular event rates.
  • Angiotensin-converting enzyme (ACE) inhibitors are a class of drugs used to treat cardiovascular diseases.
  • The Heart Outcomes Prevention Evaluation (HOPE) study aimed to evaluate the efficacy of ramipril and vitamin E in high-risk populations.

Purpose of the Study:

  • To assess the effectiveness of ramipril (an ACE inhibitor) in reducing major adverse cardiovascular events.
  • To investigate the impact of vitamin E therapy on cardiovascular outcomes.
  • To determine the benefits of ramipril in patients at high risk for cardiovascular events and diabetes.

Main Methods:

  • Randomized, double-blind, placebo-controlled trial design.
  • Inclusion of patients at high risk for cardiovascular events.
  • Administration of ramipril and vitamin E to study participants.

Main Results:

  • Ramipril significantly decreased rates of death, myocardial infarction, stroke, coronary revascularization, cardiac arrest, and heart failure.
  • Ramipril therapy also reduced the risk of diabetes-related complications and the incidence of diabetes.
  • Vitamin E therapy did not demonstrate statistically significant benefits for the evaluated outcomes.

Conclusions:

  • Ramipril is highly effective in preventing major cardiovascular events and diabetes complications in high-risk individuals.
  • The benefits of ACE inhibitors like ramipril extend beyond blood pressure reduction, involving multiple mechanisms.
  • Vitamin E is not recommended for cardiovascular event prevention based on these findings.

Related Concept Videos

Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...